Back to Journals » Clinical Ophthalmology » Volume 13

Evaluation Of The Timing Of Intravitreal Bevacizumab Injection As Adjuvant Therapy To Panretinal Photocoagulation In Patients With Diabetic Macular Edema Secondary To Diabetic Retinopathy

Authors Kartasasmita A, Harley O

Received 23 May 2019

Accepted for publication 6 September 2019

Published 26 September 2019 Volume 2019:13 Pages 1921—1926

DOI https://doi.org/10.2147/OPTH.S216790

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Nicola Ludin

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Arief Kartasasmita,1 Ohisa Harley2

1Departement of Ophthalmology, Universitas Padjadjaran/Cicendo Eye Hospital, Bandung, Indonesia; 2Netra Eye Hospital, Bandung, Indonesia

Correspondence: Arief Kartasasmita
Department of Ophthalmology, Universitas Padjadjaran, Jl. Cicendo No 4, Bandung 40141, Indonesia
Tel +62 22 4231280
Email a.kartasasmita@unpad.ac.id

Objective: To evaluate the difference in intravitreal bevacizumab (IVB) injection timing as adjuvant therapy to panretinal photocoagulation in patients with diabetic retinopathy combined with diabetic macular edema.
Methods: This was a retrospective nonrandomized study. Forty eyes with severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR) were divided into two groups; the IVB injection prior to, or after, panretinal photocoagulation. Changes in central macular thickness between the two groups were measured.
Results: There was no significant difference in change in central macular thickness between two groups after treatment (p=0.66), neither in eyes with severe NPDR groups (p=0.48) nor eyes with PDR (p=0.82).
Conclusion: IVB injection after panretinal photocoagulation gives insignificant difference in changes in central macular thickness with injection prior to laser treatment in patients with diabetic retinopathy combined with diabetic macular edema.

Keywords: diabetic retinopathy, diabetic macular edema, bevacizumab, panretinal photocoagulation


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]